PharmAla Launches Phenesafe AI Drug Discovery Platform
Slice of Healthcare Team
May 22, 2025
Key highlights
- Phenesafe AI targets novel substituted phenethylamines for patenting.
- Combines QSAR modeling and AI chemical pathway tools.
- Developed with University of Windsor via Ontario Centres of Innovation grant.
- Focused on the MDXX drug class for psychiatric and neurological treatments.
- Aligns with PharmAla’s safety-first, regulatory-driven approach.
Notable Quotes
“ Over the past year, our R&D team has been working towards the goal of creating a drug discovery platform which can be used to identify additional molecules in the MDXX class. ”
Nicholas Kadysh, CEO at PharmAla Biotech
“ The development of Phenesafe AI will help us do all of these elements more quickly, and effectively. ”
Harpreet Kaur, VP of Research at PharmAla Biotech
Why This Matters
The launch of Phenesafe AI marks a pivotal advancement in the field of psychedelic drug development, specifically within the MDXX class of compounds. By integrating advanced AI and cheminformatics, PharmAla not only streamlines the drug discovery process but also sharpens its focus on unmet neurological and psychiatric needs. This innovation strengthens PharmAla’s position as a leader in regulatory-compliant psychedelic therapeutics and paves the way for faster, safer, and more targeted drug creation in a field poised for clinical and commercial expansion.
-2e14ed90-63f5-4ce1-84fc-3fa9506b84be.png&w=3840&q=75)
